期刊文献+

TACE联合射频消融治疗复发性肝癌的临床观察

Clinical Observation of TACE Combined with Radiofrequency Ablation in the Treatment of Recurrent Liver Cancer
下载PDF
导出
摘要 目的探讨肝动脉化疗栓塞术(TACE)联合射频消融(RFA)对复发性肝细胞肝癌的治疗效果。方法选取复发性肝细胞肝癌患者70例,将患者随机分为联合组(35例)和对照组(35例),对照组行TACE治疗,联合组采用TACE联合RFA治疗。比较2组患者治疗前后免疫功能[自然杀伤(NK)细胞、T淋巴细胞分化群4+(CD4+)、CD8+]、肝功能[谷草转氨酶(AST)、丙氨酸氨基转移酶(ALT)]以及肿瘤标志物[癌胚抗原(CEA)、糖蛋白抗原199(CA199)、甲胎蛋白(AFP)]水平,比较2组临床疗效、生存期。结果治疗后,2组CD3+、CD4+、NK细胞水平均升高(P<0.05),且联合组高于对照组(P<0.05)。治疗后,2组血清CEA、AFP、CA199水平均降低(P<0.05),且联合组低于对照组(P<0.05);治疗后,2组血清ALT、AST水平均降低(P<0.05),且联合组低于对照组(P<0.05)。联合组有效率高于对照组(P<0.05);联合组生存期及生存率均高于对照组(P<0.05)。结论TACE联合RFA能够明显改善复发性肝细胞肝癌患者的免疫功能及肝功能,降低肿瘤标志物水平,提高疗效及生存率,延长生存期。 Objective To investigate the efficacy of hepatic arterial chemoembolization(TACE)combined with radiofrequency ablation(RFA)in the treatment of recurrent hepatocellular carcinoma.Methods 70 patients with recurrent hepatocellular carcinoma were selected and randomly divided them into combination group(35 cases)and control group(35 cases)accodring to random number table method.The control group was treated with TACE,while the combined group was treated with TACE combined with RFA.Compare the levels of immune function[natural killer(NK)cells,T lymphocyte differentiation group 4+(CD4+),CD8+],liver function[aspartate aminotransferase(AST),alanine aminotransferase(ALT)]and tumor markers[carcinoembryonic antigen(CEA),glycoprotein antigen 199(CA199),and alpha fetoprotein(AFP)]between the two groups before and after treatment.Compare the clinical efficacy and survival period between the two groups.Results After treatment,the cells levels of CD3+,CD4+,and NK in both groups increased(P<0.05),and the combined group was higher than the control group(P<0.05).After treatment,the serum levels of CEA,AFP,and CA199 in both groups decreased(P<0.05),and the combined group was lower than the control group(P<0.05).After treatment,the serum levels of ALT and AST in both groups decreased(P<0.05),and the combined group was lower than the control group(P<0.05).The effective rate of the combined group was higher than that of the control group(P<0.05).The survival period and survival rate in the combined group were higher than those in the control group(P<0.05).Conclusion TACE combined with RFA can significantly improve the immune function and liver function of patients with recurrent hepatocellular carcinoma,reduce the level of tumor markers,mprove the curative effect and survival rate,and prolong the survival period.
作者 许冉 常永闯 杜晓阳 曹语嫣 岳宁双 XU Ran;CHANG Yongchuang;DU Xiaoyang(The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,471003)
出处 《实用癌症杂志》 2024年第9期1493-1497,共5页 The Practical Journal of Cancer
关键词 肝动脉化疗栓塞 射频消融术 复发性肝细胞肝癌 免疫功能 生存期 肿瘤标志物 Hepatic artery chemoembolization Radiofrequency ablation Recurrent hepatocellular carcinoma immunity Survival period Tumor markers
  • 相关文献

参考文献8

二级参考文献200

  • 1Zhi-Jun Wang,Mao-Qiang Wang,Feng Duan,Peng Song,Feng-Yong Liu,Zhong-Fei Chang,Yan Wang,Jie-Yu Yan,Kai Li.Transcatheter arterial chemoembolization followed by immediate radiofrequency ablation for large solitary hepatocellular carcinomas[J].World Journal of Gastroenterology,2013,19(26):4192-4199. 被引量:24
  • 2Huo TI, Lin HC, Hsia CY, et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol,2007,102:1920-1930. 被引量:1
  • 3Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology,2001,33:464-470. 被引量:1
  • 4Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol,2002,20:1527-1536. 被引量:1
  • 5Fleming ID. AJCC/TNM cancer staging, present and future. J Surg Oncol,2001,77:233 -236. 被引量:1
  • 6Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer,1985,56:918-928. 被引量:1
  • 7Omagari K, Honda S, Kadokawa Y, et al. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol,2004,19: 805-811. 被引量:1
  • 8Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol,2003,38:207-215. 被引量:1
  • 9Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer,2002,94:1760-1769. 被引量:1
  • 10Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst,2008,100:698-711. 被引量:1

共引文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部